🔗 Share this article

During a time as director general of the World Health Organization, a former leader famously stated that all of the “simple” antimicrobials had already been found. The argument was that in tackling the urgent threat of antibiotic-resistant infections, we would struggle to discover new medicines – or conserve the current arsenal – without finding novel approaches of operating. This assessment proved accurate.

A Sluggish and Unprofitable Development Path

Since 2017, only sixteen antimicrobial agents have received broad official clearance – primarily similar derivatives of drugs already in use and thus unlikely to evade bacterial resistance for an extended period. The creation of new ones is a slow and unprofitable endeavor, given that one-off treatments are less lucrative as ones managing longer-term conditions. The overall prospect continues to be bleak.

A Spark of Hope and a New Model

Nevertheless, the news this month of two new FDA-approved drugs for gonorrhoea is good news and, importantly, confirms a innovative method of encouraging research. A particular of the new drugs, Zoliflodacin, is the product of a unique type of collaboration between a Swiss non‑profit and a pharmaceutical company. The non-profit supplied funding and managed clinical trials to defray expenses and navigate regulatory hurdles. This type of support upfront helps steer the industry towards fields of most pressing public health necessity.

This approach and another praised “subscription model” – launched to guarantee income to firms that invest in specific antimicrobials – constitute the strongest chance of maintaining a trickle of novel treatments from the current framework.

The Unavoidable Problem of Resistance

But even hurrying the development of compounds in the pipeline is not sufficient. Zoliflodacin is at times categorized as a new class of antibiotic, meaning it attacks a part of the pathogen that no other drug does, in principle forcing the bacterium to begin anew in evolving a countermeasure to it. Scientists and doctors are grateful to have a new option for gonorrhoea – which has resistant strains to all existing treatments – but warn that future resistance to this compound is certain.

As has grown customary with recent antimicrobials, exists therefore an debate about whether it should be held in reserve, rationed to highly resistant infections only – confining its application to settings where sophisticated diagnostics is available. This kind of rational strategy should be the worldwide norm, but frequently can't be implemented easily in many regions.

A Dwindling Pipeline of Discovery

On a wider scale, it is hard to see where the flow of additional novel antimicrobials we require could realistically originate. The aforementioned statement acknowledged the fact that surveying the living world for natural sources – as with penicillin – has had declining success. The application of AI has been mooted to accelerate the discovery process, although a highly-touted initial discovery identified in recent years has not yet advanced past preclinical studies. Fully lab-created compounds, that are mainly or fully lab-created, are constantly in research, but often confront the fundamental rules of chemistry – just because we envision a compound doesn't mean we can synthesise it without great difficulty.

Running Fast to Stand Still

The dominant scientific evaluation is that when it comes to antimicrobials, we must run very fast indeed just to remain in the current position. Careful, globally managed use is the sole method to maintain our advantage. Regrettably, the scale of future breakthroughs is going to seem meager compared with the therapeutic revolution of the 20th century.